First-generation V600EB-Raf inhibitors, such as dabrafenib and vemurafenib, had improved the treatment and prognosis of cancer patients, but the occurrence of paradoxical ERK1/2 activation limits their use. The gene discussed is MAPK3; the disease is cancer.